Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 6/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438411 | 1.00 | MEN1 (0.43) | MEN1KMT2ACES1RAPGEF4PARP1 | |
| SCHEMBL1040530 | 0.87 | CES1 (0.40) | MEN1KMT2ACES1PARP1NPC1 | |
| SCHEMBL31566360 | 0.86 | CES1 (0.37) | MEN1KMT2ACES1NPC1RAB9A | |
| SCHEMBL1042360 | 0.86 | CES1 (0.37) | MEN1KMT2ACES1NPC1RAB9A | |
| SCHEMBL5897686 | 0.83 | CES1 (0.38) | MEN1KMT2ACES1 | |
| SCHEMBL26550837 | 0.80 | DRD1 (0.38) | CES1PARP1BCL2L1BADALDH1A1 | |
| SCHEMBL29424782 | 0.79 | DRD1 (0.39) | CES1PARP1BCL2L1BAD | |
| SCHEMBL665033 | 0.79 | DRD1 (0.39) | CES1PARP1BCL2L1BAD | |
| SCHEMBL29924184 | 0.79 | DRD1 (0.39) | CES1PARP1BCL2L1BAD | |
| SCHEMBL9192628 | 0.78 | DRD1 (0.38) | CES1PARP1BCL2L1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | claimed |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3950672-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | Kyowa Pharma Chemical Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-10294193-B2 | Compound, and flavor composition and/or fragrance composition containing same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-05-21 | — | — | US | disclosed |
| EP-3199513-B1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-10029969-B2 | Method of producing optically-active aldehyde | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10029968-B2 | Process for producing alcohol analogue | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-9896402-B2 | Method for preventing decrease in optical purity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-0781749-B1 | Process for producing optically active benzhydrol compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6342644-B1 | MULTISTAGE PROCESS OF HYDROGENATION WITH PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-29 | — | — | US | disclosed |
| US-20020007094-A1 | Method for producing 1-menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-1153908-A2 | Method for producing 1-menthol | Takasago International Corporation (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-0673911-B1 | Process for producing optically active carboxylic acids and chiral ligands for this purpose | TAKASAGO PERFUMERY CO LTD (JP) | 1999-01-20 | — | — | EP | disclosed |
| EP-0781749-A2 | Process for producing optically active benzhydrol compounds | Takasago International Corporation (JP) | 1997-07-02 | — | — | EP | disclosed |
| US-5563295-A | HYDROGENATION OF OLEFINIC CARBOXYLIC ACID USING RUTHENIUM-PHOSPHINE COMPLEX CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0673911-A1 | Process for producing optically active carboxylic acids and chiral ligands for this purpose | Takasago International Corporation (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | MEN1 2300/4885KMT2A 2066/4885CES1 1327/4885 |
| US-10029969-B2 | Method of producing optically-active aldehyde | ALDH3A1, ALDH1A2, ADH1A | MEN1 3945/4885KMT2A 3097/4885CES1 574/4885 |
| US-10294193-B2 | Compound, and flavor composition and/or fragrance composition containing same | FZD7, TAS1R1, TAS2R5 | MEN1 1763/4885KMT2A 994/4885CES1 1911/4885 |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | HSD17B10, HSD17B1, HSD17B12 | MEN1 2881/4885KMT2A 3056/4885CES1 155/4885 |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | ADH1A, ADH1C, ADH5 | MEN1 290/4885KMT2A 1658/4885CES1 1128/4885 |
| US-20020007094-A1 | Method for producing 1-menthol | HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PHOSPHO1 | MEN1 570/4885KMT2A 3335/4885CES1 2700/4885 |
| US-10029968-B2 | Process for producing alcohol analogue | ADH1A, ADH1C, ADH5 | MEN1 290/4885KMT2A 1658/4885CES1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.